QT-Prolongation in Lung Transplantation (TX-QTC)

Hannover Medical School (MHH)

Status

Unknown

Conditions

Disorder Related to Lung Transplantation

Treatments

Device: Electrocardiography

Study type

Observational

Funder types

Other

Identifiers

2602-2015

Details and patient eligibility

About

Experimental intervention: electrocardiography. Control intervention: none

Duration of intervention per patient/subject:

5 min, observation 6 months

Key inclusion criteria:

Key exclusion criteria:

• no informed consent

Full description

Primary endpoint:

• prevalence of significant QTc-interval prolongation (500 msec or above) after lung transplantation

Key secondary endpoint(s):

prevalence of any QTc-interval prolongation (>440 msec ) after lung transplantation
prevalence of PQ prolongation (200 msec sec or above) after lung transplantation
prevalence of QRS prolongation (120 msec or above) after lung transplantation
prevalence of QTc-prolonging drugs in drug regimen before and after lung transplantation
influence of long-term neo-macrolide (e.g. azithromycin) on QTc interval after lung transplantation
intra-individual difference of QTc interval before and after lung transplantation
incidence of any QTc-interval prolongation(>440 msec ) after lung transplantation
incidence of any QTc-interval prolongation (>440 msec or increase by 50msec or above) after initiation of new QTc prolonging drugs (especially neo-macrolides)
reversal of QTc-interval prolongation (440 msec or lower or decrease by 50msec or above) after stopping any QTc prolonging drug
Assessment of safety:
Incidence of new onset heart rhythm disorder during 6 months of follow-up